Commodore Capital LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Commodore Capital LP reported 36 stock positions worth $1.7 billion. Its top holding was Relay Therapeutics (RLAY) at 9.8% of the portfolio, followed by Alkermes (ALKS, 8.6%) and Enliven Therapeutics (ELVN, 7.4%). Compared with Q4 2025, it opened 12 new positions, sold out of 9, added to 7 and reduced 6. The biggest buy was a new position in Erasca (ERAS) and the biggest sale an exit from Terns Pharmaceuticals (TERN).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001831942
- Portfolio Value
- $1.7B (Q1 2026)
- SEC Filing
- 0001831942-26-000025 ↗ filed May 15, 2026
Holdings Value
Holdings 36 stocks · $1.7B
| RLAY Relay Therapeutics Inc. | 9.79% | 17,000,000 | $169.2M | No change |
| ALKS Alkermes PLC | 8.59% | 4,200,000 | $148.5M | Add +18.3% |
| ELVN Enliven Therapeutics Inc. | 7.43% | 3,275,000 | $128.4M | Reduce -30.2% |
| COGT Cogent Biosciences Inc. | 6.43% | 2,888,007 | $111.2M | Add +31.5% |
| SYRE Spyre Therapeutics Inc. | 5.58% | 1,912,380 | $96.5M | Reduce -19.9% |
| TYRA Tyra Biosciences Inc. | 5.48% | 2,475,000 | $94.8M | Reduce -26.7% |
| CLDX Celldex Therapeutics Inc. | 4.95% | 2,696,616 | $85.5M | Add +5.1% |
| NUVL Nuvalent Inc. Class A | 4.94% | 833,600 | $85.4M | Add +51.6% |
| AMLX Amylyx Pharmaceuticals Inc. | 4.54% | 5,650,000 | $78.5M | No change |
| KYMR Kymera Therapeutics Inc. | 3.61% | 750,000 | $62.5M | No change |
| ANRO Alto Neuroscience Inc. | 3.54% | 2,723,196 | $61.2M | Add +49.4% |
| PHVS Pharvaris NV | 3.14% | 1,918,970 | $54.2M | Add +1.6% |
| ERAS Erasca Inc. | 2.97% | 3,175,000 | $51.4M | New |
| DMRA Damora Therapeutics Inc. | 2.91% | 1,939,000 | $50.2M | New |
| XENE Xenon Pharmaceuticals Inc. | 2.78% | 825,000 | $48.0M | Reduce -54.2% |
| DFTX Definium Therapeutics Inc. | 2.19% | 2,000,000 | $37.8M | No change |
| LBRX LB Pharmaceuticals Inc. | 2.14% | 1,500,000 | $37.0M | No change |
| EYPT Eyepoint Inc. | 2.11% | 2,825,000 | $36.4M | New |
| NRIX Nurix Therapeutics Inc. | 2.04% | 2,275,000 | $35.3M | No change |
| CRVS Corvus Pharmaceuticals Inc. | 1.91% | 2,258,735 | $33.0M | New |
| ASMB Assembly Biosciences Inc. | 1.61% | 1,000,000 | $27.8M | No change |
| CATX Perspective Therapeutics Inc. | 1.53% | 6,336,782 | $26.4M | New |
| SLNO Soleno Therapeutics Inc. | 1.26% | 652,432 | $21.8M | Reduce -45.6% |
| OCUL Ocular Therapeutix Inc. | 1.26% | 2,575,000 | $21.8M | New |
| IPSC Century Therapeutics Inc. | 1.14% | 8,695,652 | $19.7M | New |
| ZURA Zura Bio Ltd. | 1.12% | 3,250,000 | $19.3M | New |
| SABS Sab Biotherapeutics Inc. | 0.98% | 4,401,500 | $16.9M | No change |
| PALI Palisade Bio Inc. | 0.73% | 7,181,062 | $12.6M | Reduce -37.3% |
| KPTI Karyopharm Therapeutics Inc. | 0.63% | 1,950,000 | $10.9M | New |
| IKT Inhibikase Therapeutics Inc. | 0.52% | 5,397,488 | $9.1M | No change |
| ANTX AN2 Therapeutics Inc. | 0.46% | 2,333,713 | $8.0M | New |
| PEPG Pepgen Inc. | 0.46% | 4,475,000 | $7.9M | Add +31.6% |
| AVTX Avalo Therapeutics Inc. | 0.42% | 483,000 | $7.2M | No change |
| HLXC Helix Acquisition Corp. Class A | 0.29% | 500,000 | $5.1M | New |
| LONA Leonabio Inc. | 0.28% | 464,398 | $4.8M | No change |
| RLMD Relmada Therapeutics Inc. | 0.26% | 633,901 | $4.4M | New |
Portfolio Sells Q4 2025 → Q1 2026
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −3.97 |
| ORKA Oruka Therapeutics Inc. | Sold out | 0.00% | −3.54 |
| PTGX Protagonist Therapeutics Inc. | Sold out | 0.00% | −2.62 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -54.2% | 2.78% | −2.59 |
| SLNO Soleno Therapeutics Inc. | Reduce -45.6% | 1.26% | −2.43 |
| CTMX Cytomx Therapeutics Inc. | Sold out | 0.00% | −2.18 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −1.66 |
| PALI Palisade Bio Inc. | Reduce -37.3% | 0.73% | −1.06 |
| REPL Replimune Group Inc. | Sold out | 0.00% | −0.92 |
| CTNM Contineum Therapeutics Inc. Class A | Sold out | 0.00% | −0.62 |
| RAPT Rapt Therapeutics Inc. | Sold out | 0.00% | −0.56 |
| TYRA Tyra Biosciences Inc. | Reduce -26.7% | 5.48% | −0.42 |
| DRUG Bright Minds Biosciences Inc. | Sold out | 0.00% | −0.10 |
| SYRE Spyre Therapeutics Inc. | Reduce -19.9% | 5.58% | +0.37 |
| ELVN Enliven Therapeutics Inc. | Reduce -30.2% | 7.43% | +2.62 |
Portfolio Buys Q4 2025 → Q1 2026
| ERAS Erasca Inc. | New | 2.97% | +2.97 |
| DMRA Damora Therapeutics Inc. | New | 2.91% | +2.91 |
| EYPT Eyepoint Inc. | New | 2.11% | +2.11 |
| ALKS Alkermes PLC | Add +18.3% | 8.59% | +1.98 |
| CRVS Corvus Pharmaceuticals Inc. | New | 1.91% | +1.91 |
| CATX Perspective Therapeutics Inc. | New | 1.53% | +1.53 |
| ANRO Alto Neuroscience Inc. | Add +49.4% | 3.54% | +1.38 |
| OCUL Ocular Therapeutix Inc. | New | 1.26% | +1.26 |
| NUVL Nuvalent Inc. Class A | Add +51.6% | 4.94% | +1.26 |
| COGT Cogent Biosciences Inc. | Add +31.5% | 6.43% | +1.24 |
| IPSC Century Therapeutics Inc. | New | 1.14% | +1.14 |
| ZURA Zura Bio Ltd. | New | 1.12% | +1.12 |
| KPTI Karyopharm Therapeutics Inc. | New | 0.63% | +0.63 |
| ANTX AN2 Therapeutics Inc. | New | 0.46% | +0.46 |
| CLDX Celldex Therapeutics Inc. | Add +5.1% | 4.95% | +0.31 |
| HLXC Helix Acquisition Corp. Class A | New | 0.29% | +0.29 |
| RLMD Relmada Therapeutics Inc. | New | 0.26% | +0.26 |
| PHVS Pharvaris NV | Add +1.6% | 3.14% | −0.35 |
| PEPG Pepgen Inc. | Add +31.6% | 0.46% | −1.02 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $1.7B | RLAY, ELVN, ALKS, COGT, AMLX |
| Q1 2026 | 36 | $1.7B | RLAY, ALKS, ELVN, COGT, SYRE |
| Q4 2025 | 33 | $1.5B | RLAY, ALKS, TYRA, XENE, SYRE |
| Q3 2025 | 37 | $2.0B | MRUS, NUVL, XENE, COGT, ELVN |
| Q2 2025 | 33 | $1.4B | MRUS, NUVL, XENE, ELVN, AGIO |
| Q1 2025 | 31 | $1.4B | MRUS, NUVL, ELVN, SLNO, XENE |
| Q4 2024 | 31 | $1.4B | MRUS, PCVX, NUVL, XENE, ELVN |
| Q3 2024 | 36 | $1.6B | MRUS, VERA, XENE, PCVX, ELVN |
| Q2 2024 | 35 | $1.5B | MRUS, NUVL, XENE, PCVX, ELVN |
| Q1 2024 | 39 | $1.5B | MRUS, VERA, NUVL, XENE, SYRE |